We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Nitrite Therapy for Babies with Pulmonary Hypertension

By HospiMedica staff writers
Posted on 12 Oct 2004
A study has found that an inhaled nitrite spray can rapidly reduce persistent pulmonary hypertension of the newborn (PPHN) in an animal model.

Premature newborns and those with pneumonia or heart problems frequently develop PPHN, an often-fatal disease that causes high blood pressure in an infant's lungs and places the baby in a low-oxygen state. More...
Researchers at the U.S. National Institutes of Health (NIH; www.nih.gov) decided to try a nitrite spray in an animal model. Nitrite dilates blood vessels in the lungs, reacts with de-oxygenated hemoglobin, and is converted into nitric oxide when the body is in a low-oxygen state. Nitric oxide (NO) helps to regulate blood flow, so the researchers thought the naturally occurring conversion of nitrite to nitric oxide might help babies with PPHN by lowering lung blood pressure and raising oxygen levels.

"Nitrite inhalation rapidly reduced pulmonary pressures by 65%,” said Christian Hunter, Ph.D., a fourth-year medical student at Loma Linda University School of Medicine (CA, USA). "The nitrite had a much longer effect than the nitric oxide. In one case, we administered the inhaled nitrite for 20 minutes and the high blood pressure levels were reversed for an hour.”

The researchers mixed nitrite with plain saline solution, and administered it with a plastic inhaler. They note that more research is needed to determine the safety and efficacy of inhaled nitrite for human use. The study results were reported in the September 12, 2004, online edition of Nature Medicine.





Related Links:
NIH
Loma Linda U. Med. School

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.